The dilutive offering is the dominant near-term catalyst, likely weighing on the stock despite positive clinical data. Monitor for potential price support from the underwriter's stabilizing activities and any subsequent clinical milestone updates ahead of the mid-2027 BLA submission.
Price Chart
Executive Summary
Immix Biopharma is offering 11,363,637 shares of common stock at $11.00 per share via an underwritten public offering led by J.P. Morgan, raising approximately $117.1 million in net proceeds. The offering is priced at a slight 4.1% discount to the prior close of $11.47. Proceeds will fund NXC-201 clinical development and working capital. The filing coincides with a positive clinical data update showing an 89% complete response rate in the NEXICART-2 trial, but the dilutive impact of the offering is the primary near-term event.
Key Facts
- Offering of 11,363,637 shares at $11.00 per share, raising ~$117.1 million net proceeds.
- Public offering price represents a ~4.1% discount to the $11.47 closing price on September 28, 2026.
- Shares outstanding will increase from ~71.7M to ~83.1M post-offering, a ~15.9% dilution.
- New investors face immediate dilution of $6.83 per share (62% of offering price).
- Net tangible book value per share increases from $3.19 to $4.17 post-offering.
- Underwriters: J.P. Morgan Securities LLC (sole book-runner).
- 90-day lock-up on company and insiders.
- Concurrent positive clinical data: 89% CR rate in NEXICART-2 trial; BLA submission planned mid-2027.
Financial Impact
~$117.1 million net proceeds raised; ~15.9% dilution to existing shareholders.
Risk Factors
- Immediate dilution of ~15.9% for existing shareholders.
- Potential downward price pressure from the discounted offering and future ATM sales ($31.6M remaining).
- Clinical-stage biotech risk: NXC-201 still requires regulatory approval; BLA submission not until mid-2027.
- Need for additional capital beyond this raise to fund operations and commercialization.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-044771 |
| Document: 0001493152-26-044771-index-headers.html | 0001493152-26-044771 |
| Document: 0001493152-26-044771-index.html | 0001493152-26-044771 |
| Document: 0001493152-26-044771.txt | 0001493152-26-044771 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $10.23 $9.29 | ▲ +9.19% | ▲ +10.49% | $8.06 (+21.21%) |
Sep 29, 2026 28d ago | 424B5 | $10.54 $9.64 | ▲ +8.54% | ▲ +10.49% | $8.06 (+23.53%) |
Sep 29, 2026 28d ago | 8-K | $10.54 $9.64 | ▼ −8.54% | ▼ −10.49% | $8.06 (−23.53%) |
Jul 20, 2026 14w ago | 8-K | $8.80 $8.52 | ▼ −3.18% | ▼ −2.76% | $8.06 (−8.41%) |
May 21, 2026 22w ago | 8-K | $8.78 $9.22 | ▼ −5.01% | ▼ −3.35% | $8.06 (+8.20%) |
May 21, 2026 22w ago | Press Release | $8.67 $9.00 | ▲ +3.81% | ▲ +1.96% | $8.06 (−7.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers